BilliontoOne

About BilliontoOne

BilliontoOne is a biotechnology company focused on developing advanced diagnostic tools. Their core technology leverages single-molecule analysis to detect rare biological events, such as circulating tumor DNA (ctDNA) in blood. This enables highly sensitive and early cancer detection, potentially transforming cancer screening and monitoring. The company aims to provide non-invasive methods for personalized medicine, allowing for earlier intervention and improved patient outcomes. Their platform is designed for broad applicability across various cancer types and stages, offering a significant advancement in the field of liquid biopsy and precision oncology.